Literature DB >> 16844773

Benefit of farnesoid X receptor inhibition in obstructive cholestasis.

Catherine Stedman1, Christopher Liddle, Sally Coulter, Junichiro Sonoda, Jacqueline G Alvarez, Ronald M Evans, Michael Downes.   

Abstract

The nuclear hormone receptors farnesoid X receptor (FXR) and pregnane X receptor have been implicated in regulating bile acid, lipid, carbohydrate, and xenobiotic metabolism. Bile duct ligation was used to increase endogenous bile acids and evaluate the roles of these receptors in modulating cholestatic liver injury. FXR knockout (KO) mice were found to be protected from obstructive cholestasis. Concurrent deletion of FXR also could ameliorate an increase in liver injury that is seen usually in pregnane X receptor KO mice with cholestasis. Mechanisms proposed for this protection include the lowering of bile acid concentrations and altered expression of the hepatic transporters Mdr1, Mdr2, BSEP, and Mrp4. FXR KO mice also exhibit a biphasic lipid profile after bile duct ligation, with an increase in high-density lipoprotein cholesterol and triglycerides by day 6. The expression of apolipoprotein AV was reduced in these mice, implicating FXR in triglyceride regulation. We show that FXR modulates cholestasis by controlling bile acids within the hepatocyte and is involved in bile acid synthesis, bile excretion via BSEP, and serum export via Mrp4. This study strongly suggests a potential clinical role for FXR antagonists in the treatment of obstructive cholestatic liver disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16844773      PMCID: PMC1544085          DOI: 10.1073/pnas.0604772103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.

Authors:  T W Synold; I Dussault; B M Forman
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

2.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

Authors:  W Xie; A Radominska-Pandya; Y Shi; C M Simon; M C Nelson; E S Ong; D J Waxman; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Alan F Hofmann; Dietrich Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-10       Impact factor: 4.052

Review 4.  The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity.

Authors:  H W Harris; J E Gosnell; Z L Kumwenda
Journal:  J Endotoxin Res       Date:  2000

5.  Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR).

Authors:  Junichiro Sonoda; Wen Xie; John M Rosenfeld; Joyce L Barwick; Philip S Guzelian; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

6.  Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor.

Authors:  W R Howard; J A Pospisil; E Njolito; D J Noonan
Journal:  Toxicol Appl Pharmacol       Date:  2000-03-01       Impact factor: 4.219

7.  An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing.

Authors:  L A Pennacchio; M Olivier; J A Hubacek; J C Cohen; D R Cox; J C Fruchart; R M Krauss; E M Rubin
Journal:  Science       Date:  2001-10-05       Impact factor: 47.728

8.  Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

Authors:  C J Sinal; M Tohkin; M Miyata; J M Ward; G Lambert; F J Gonzalez
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

9.  Regulation of drug transporter gene expression by nuclear receptors.

Authors:  Jeff L Staudinger; Ajay Madan; Kathleen M Carol; Andrew Parkinson
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

10.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.

Authors:  Michael Downes; Mark A Verdecia; A J Roecker; Robert Hughes; John B Hogenesch; Heidi R Kast-Woelbern; Marianne E Bowman; Jean-Luc Ferrer; Andrew M Anisfeld; Peter A Edwards; John M Rosenfeld; Jacqueline G A Alvarez; Joseph P Noel; K C Nicolaou; Ronald M Evans
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

View more
  56 in total

1.  A novel heterozygous NR1H4 termination codon mutation in idiopathic infantile cholestasis.

Authors:  Xiu-Qi Chen; Lin-Lin Wang; Qing-Wen Shan; Qing Tang; Ya-Nan Deng; Shu-Jun Lian; Xiang Yun
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts.

Authors:  Barbara Renga; Andrea Mencarelli; Marco Migliorati; Sabrina Cipriani; Claudio D'Amore; Eleonora Distrutti; Stefano Fiorucci
Journal:  Inflamm Res       Date:  2011-01-29       Impact factor: 4.575

Review 3.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

4.  β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.

Authors:  Michael D Thompson; Akshata Moghe; Pamela Cornuet; Rebecca Marino; Jianmin Tian; Pengcheng Wang; Xiaochao Ma; Marc Abrams; Joseph Locker; Satdarshan P Monga; Kari Nejak-Bowen
Journal:  Hepatology       Date:  2018-01-26       Impact factor: 17.425

5.  Aryl hydrocarbon receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin enhances liver damage in bile duct-ligated mice.

Authors:  Jun Ozeki; Shigeyuki Uno; Michitaka Ogura; Mihwa Choi; Tetsuyo Maeda; Kenichi Sakurai; Sadanori Matsuo; Sadao Amano; Daniel W Nebert; Makoto Makishima
Journal:  Toxicology       Date:  2010-11-21       Impact factor: 4.221

6.  Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists.

Authors:  Carmen Festa; Claudia Finamore; Silvia Marchianò; Francesco Saverio Di Leva; Adriana Carino; Maria Chiara Monti; Federica Del Gaudio; Sara Ceccacci; Vittorio Limongelli; Angela Zampella; Stefano Fiorucci; Simona De Marino
Journal:  ACS Med Chem Lett       Date:  2019-01-10       Impact factor: 4.345

Review 7.  FXR and PXR: potential therapeutic targets in cholestasis.

Authors:  Johan W Jonker; Christopher Liddle; Michael Downes
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-20       Impact factor: 4.292

8.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12

9.  Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice.

Authors:  Maxwell Afari Gyamfi; Yuji Tanaka; Lin He; Curtis D Klaassen; Yu-Jui Yvonne Wan
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-08       Impact factor: 4.219

10.  A grape seed procyanidin extract inhibits HDAC activity leading to increased Pparα phosphorylation and target-gene expression.

Authors:  Laura E Downing; Bradley S Ferguson; Kelvin Rodriguez; Marie-Louise Ricketts
Journal:  Mol Nutr Food Res       Date:  2016-10-28       Impact factor: 5.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.